Our findings show that MGNs simultaneously track CD8+ T cells and VEGFR2+ expressing tumor cells in 4T1 tumors in vivo with multiplexed SERS imaging, enabling us to predict treatment response to STING + TLR9 immunotherapy. Here, CD8A is linked to neoplasm.